Composition, form of production and packaging
? The gel for external use is yellowish, translucent, with a fruity smell.
1 g
chondroitin sodium sulfate 50 mg
Auxiliary substances: dimethylsulfoxide (dimexide) - 100 mg, propylene glycol (1,2-propanediol) - 50 mg, isopropanol (isopropyl alcohol, 2-propanol) - 50 mg, ethanol (ethyl alcohol) - 200 mg, sodium disulfite (sodium metabisulfite ) - 0.5 mg, methylparahydroxybenzoate (nipagin, methylparaben) 1.2 mg, propyl parahydroxybenzoate (nipazole, propylparaben) 0.3 mg, carbomer (carbopol) 35 mg, orange flavoring (orange flavoring aroma) 5 mg, purified water up to 1 g.
20 g - aluminum tubes (1) - packs of cardboard.
25 grams - tubes of aluminum (1) - packs of cardboard.
30 g - aluminum tubes (1) - cardboard packs.
35 g - aluminum tubes (1) - cardboard packs.
40 g - aluminum tubes (1) - packs of cardboard.
? Ointment for external use of light yellow color with the smell of dimethylsulfoxide.
1 g
chondroitin sodium sulfate 50 mg
Auxiliary substances: dimethylsulfoxide (dimexide) - 100 mg, lanolin - 150 mg (lanolin anhydrous, wax wool), Vaseline - 485 mg, distilled monoglycerides - 15 mg, purified water - up to 1 g.
30 g - aluminum tubes (1) - cardboard packs.
50 g - aluminum tubes (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2012.
PHARMACHOLOGIC EFFECT
Stimulator of tissue regeneration for external use. Chondroxide В® has a combined action:
- slows the progression of osteoarthritis and osteochondrosis;
- has analgesic effect;
- has an anti-inflammatory effect;
-stimulates the restoration of articular cartilage;
- improves mobility of joints;
- reduces the swelling of the joints.
Due to the optimal combination of gel components, the mutual enhancement of their analgesic and anti-inflammatory effects is noted. The use of the drug Chondroxide В® can reduce the dose of NSAIDs taken. Chondroxide В® contains a natural component of chondroitin sulfate (high molecular weight mucopolysaccharide), which takes part in the construction of cartilaginous tissue. Chondroitin sulfate improves phosphoric-calcium metabolism in cartilaginous tissue; reduces the activity of enzymes that destroy cartilaginous tissue; inhibits the processes of degeneration (destruction) of cartilaginous tissue; stimulates the synthesis of glycosaminoglycans; prevents the collapse of connective tissue. This leads to a decrease in soreness and increased mobility of the affected joints.
PHARMACOKINETICS
Chondroxide В® gel is well absorbed. According to the data obtained in experimental studies in mice using radiolabelled 3 H-chondroitin sulfate, the chondroitin sulphate absorption index is 14%. Dimethyl sulfoxide promotes better penetration of chondroitin sulfate through cell membranes deep into tissues.
Chondroitin sulfate after application of the drug Chondroxide gel on the skin quickly and selectively enters the joint with the attainment of C max after 30 minutes and the subsequent biphasic excretion of the preparation from the cartilage tissue. Completion of the rapid phase of withdrawal occurs 1 h after application. The retention time of the drug in the joint is 5 hours.
INDICATIONS
- treatment and prevention of osteoarthritis of peripheral joints and osteochondrosis of the spine.
DOSING MODE
Ointment or gel should be applied 2-3 times / day on the skin above the lesion. The ointment is rubbed until completely absorbed for 2-3 minutes. The course of treatment with ointment is 2-3 weeks. The gel is easily rubbed with patting movements for 2-3 minutes until completely absorbed. The course of gel treatment is from 2-3 weeks to 2-3 months. If necessary, repeat the treatment.
SIDE EFFECT
Possible: allergic reactions.
CONTRAINDICATIONS
- damage to the skin in the area of ​​application (for the gel);
- Hypersensitivity to the components of the drug.
Caution should be used Chondroxide В® in the dosage form of gel and ointment during pregnancy, during lactation, in patients of childhood (efficacy and safety not established).
PREGNANCY AND LACTATION
With caution and after consulting a doctor, Chondroxide В® should be used in the form of a gel and ointment during pregnancy and lactation (breastfeeding).
APPLICATION FOR CHILDREN
Caution should be applied Chondroxide В® in the drug form of gel and ointment in patients of childhood (efficacy and safety not established).
SPECIAL INSTRUCTIONS
Avoid getting the drug on the mucous membranes and open wounds.
Upon contact with skin or clothing, the gel is easily washed off with water, leaving no residue.
Use in Pediatrics
With caution and after consulting a doctor, the drug should be used in children (efficacy and safety of use in pediatrics are not established).
OVERDOSE
At present, cases of overdose of Chondroxide В® have not been reported.
DRUG INTERACTION
Drug interaction of the drug Chondroxide В® is not described.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
Ointment should be stored out of reach of children, protected from light at a temperature of 2 В° to 20 В° C. Shelf life - 3 years.
The gel should be stored out of the reach of children at a temperature of no higher than 25 В° C. Shelf life - 2 years.
